PT-141 10 mg

PT‑141 (Bremelanotide) by Hilma Biocare: libido‑enhancement & melanogenesis

PT‑141 is a synthetic peptide analogue of melanotan‑2 that selectively activates melanocortin receptors MC3R and MC4R. By acting on the central nervous system as well as peripheral vasculature, it boosts sexual desire in both men and women while also stimulating melanin production for a tanning effect.

Main functions of PT‑141

• Sexual arousal stimulation: Activates MC3R/MC4R in the brain’s medial pre‑optic area, increasing dopamine and serotonin release and enhancing libido.
• Cardiovascular activation: Improves blood flow to pelvic organs, supporting erection and genital engorgement.
• Melanogenesis: Promotes melanin synthesis in melanocytes, leading to skin tanning.
• Mood & anxiety modulation: Through central melanocortin pathways it can improve mood and reduce anxiety.

Dosage & application

• Form: Lyophilised PT‑141 for sub‑cutaneous injection (intramuscular use is possible but less common).
• Initial dose: 0.1–0.3 mg sub‑cutaneously.
• Usual titration: Increase gradually to 0.5–1 mg based on efficacy and tolerance.
• Weight‑based dosing: Approx. 10 µg · kg⁻¹ (e.g., 70 kg → 0.7 mg).
• Maximum: Do not exceed 1.5 mg per injection; dosing more than once daily is not recommended.
• Onset / peak: Effects begin within 2 h, peak at 3–4 h, lasting 8–10 h.
• Typical protocol (research/clinical):
  • Weeks 1‑2: 0.1 mg once daily (or every other day) to assess tolerance.
  • Weeks 3‑4: 0.3 mg once daily.
  • Weeks 5‑6: 0.5 mg once daily.
  • Weeks 7 +: 0.7‑1 mg once daily as needed, not exceeding three times per week for long‑term use.
• Monitoring: Track blood pressure, heart rate, and any mood changes; adjust dose accordingly.

Contra‑indications

• Uncontrolled hypertension or cardiovascular disease.
• Severe liver or kidney impairment.
• Cancer, pregnancy, lactation.
• Known hypersensitivity to PT‑141 or any excipients.

Drug interactions

• Avoid concurrent use with other vasodilators, antihypertensives, or agents that affect serotonin/dopamine pathways without medical supervision.

Side effects

• Common: nausea, flushing, headache, transient rise in blood pressure.
• Rare: local injection site reactions, dizziness.
• Report any adverse events to a healthcare professional.

Compatibility with other products

PT‑141 can be combined safely with other performance‑enhancing compounds (peptides, anabolic steroids, growth hormone, etc.) when overseen by a physician, allowing synergistic anti‑fatigue or aesthetic stacks.

Conclusion

PT‑141 by Hilma Biocare offers a clinically validated approach to enhance libido, improve mood, and promote tanning. Precise dosing, careful monitoring, and professional supervision make it a versatile option for athletes, bodybuilders, and anyone seeking sexual‑performance support.